Market Overview:
The global cell-free DNA (cfDNA) testing market is expected to grow at a CAGR of 16.5% from 2018 to 2030. The growth in the cfDNA testing market can be attributed to the increasing demand for non-invasive prenatal tests (NIPT), rising prevalence of cancer, and technological advancements in cfDNA sequencing platforms. The donor-derived cell-free DNA segment is expected to dominate the global cfDNA testing market during the forecast period. This can be attributed to the increasing demand for donor sperm and eggs, growing number of single parents, and rising incidence of genetic disorders. The hospital segment is expected to account for the largest share of the global cfDNA testing market in 2018. This can be attributed to factors such as increase in number of pregnant women opting for NIPT, rise in awareness about NIPT among healthcare professionals and patients, and growing adoption rates of NIPT by hospitals across regions.
 Testing Industry Outlook.svg)
Product Definition:
Cell-free DNA (cfDNA) testing is a laboratory test that uses pieces of DNA from the blood to screen for genetic disorders. cfDNA testing can be used to screen for Down syndrome, Edwards syndrome, and Patau syndrome. The importance of cfDNA testing is that it can detect these disorders before birth.
Donor-Derived Cell-Free DNA (DdcfDNA):
The cfDNA Testing market is in its nascent stage and is expected to grow at a lucrative rate over the forecast period. cfDNA, also known as donor-derived cell-free DNA (DdcfDNA), has been identified as a potential biomarker for diagnosis of genetic diseases.
Circulating Cell-Free Tumor DNA (CtDNA):
Circulating cell-free tumor DNA (CtDNA) and Cell-Free DNA (cfDNA) are two types of genetic material extracted from tumors. Circulating cell-free tumor DNA is the genetic material that remains behind after a complete separation of the cancer cells in clinical laboratories. It is mainly used for detecting cancer, but it also has other applications such as diagnosis of HIV, H1N1 flu, and testing for certain infections like hepatitis B & C.
Application Insights:
The hospital application segment dominated the global market in 2017. The increasing prevalence of cancer and the need for sensitive, rapid, and accurate molecular diagnostic tests are some of the factors contributing to its dominance over other applications. Hospital-based testing is considered more sensitive than laboratory-based testing due to various advantages such as lower cost, faster turnaround time, greater convenience among others.
Circulating cell-free tumor DNA (CtDNA) analysis is anticipated to witness lucrative growth during the forecast period owing to its increased use in monitoring tumor response following treatment with surgery or radiation therapy. It has been proven that circulating cell-free DNA can be used as a biomarker for evaluating response after treatment with external beam radiation therapy or brachytherapy for patients suffering from gynecological cancers such as endometrial cancer and cervical cancer respectively.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of centers and laboratories that offer cfDNA testing services, high adoption rate for technologically advanced medical products, and increasing government initiatives. For instance, in February 2018, Foundation Medicine introduced free DNA testing program through its direct-to-consumer platform Genome Test Express (GTE). The company offered genetic screening for more than 80 rare diseases through this program.
Asia Pacific is expected to grow at a lucrative CAGR during the forecast period owing to an increase in cfDNA tests being performed due to rising incidences of cancer & genetic disorders among Asians coupled with growing healthcare awareness levels amongst people living in this region.
Growth Factors:
- Increasing demand for non-invasive prenatal testing: cfDNA testing is a non-invasive prenatal screening test that can be used to detect certain genetic abnormalities in the fetus. The demand for cfDNA testing is increasing due to its ability to provide accurate results with a high degree of certainty.
- Growing awareness about the benefits of cfDNA testing: There is growing awareness about the benefits of cfDNA testing, such as its ability to provide early detection of genetic disorders and improve pregnancy outcomes. This is driving more people to opt for this type of test.
- Advances in technology and increasing availability of tests: The technological advances being made in the field of genomics are making it possible to develop new and improved tests for detecting genetic abnormalities, which is helping to drive growth in the cfDNA Testing market. Additionally, there has been an increase in the number of private laboratories offering these tests, making them more widely available and affordable than ever before.
Scope Of The Report
Report Attributes
Report Details
Report Title
Cell-Free DNA (cfDNA) Testing Market Research Report
By Type
Donor-Derived Cell-Free DNA (DdcfDNA), Circulating Cell-Free Tumor DNA (CtDNA), Cell-Free Fetal DNA (NIPT)
By Application
Hospital, Ambulatory Surgical Centers, Cancer Research Institutes
By Companies
Agilent Technology, Allenex, Biocept, Biodesix, CareDx, Guardant Health, Illumania, Invited, Natera, Quest Diagnostics, Roche Holdings, Sequenom, Trovagene
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
180
Number of Tables & Figures
126
Customization Available
Yes, the report can be customized as per your need.
Global Cell-Free DNA (cfDNA) Testing Market Report Segments:
The global Cell-Free DNA (cfDNA) Testing market is segmented on the basis of:
Types
Donor-Derived Cell-Free DNA (DdcfDNA), Circulating Cell-Free Tumor DNA (CtDNA), Cell-Free Fetal DNA (NIPT)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Ambulatory Surgical Centers, Cancer Research Institutes
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Agilent Technology
- Allenex
- Biocept
- Biodesix
- CareDx
- Guardant Health
- Illumania
- Invited
- Natera
- Quest Diagnostics
- Roche Holdings
- Sequenom
- Trovagene
 Testing Market Overview.svg)
Highlights of The Cell-Free DNA (cfDNA) Testing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Donor-Derived Cell-Free DNA (DdcfDNA)
- Circulating Cell-Free Tumor DNA (CtDNA)
- Cell-Free Fetal DNA (NIPT)
- By Application:
- Hospital
- Ambulatory Surgical Centers
- Cancer Research Institutes
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cell-Free DNA (cfDNA) Testing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Testing Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cell-free DNA testing is a type of genetic testing that uses isolated DNA from cells that are not associated with the person being tested. This type of testing can be used to detect certain types of cancer, inherited diseases, and other conditions.
Some of the major companies in the cell-free dna (cfdna) testing market are Agilent Technology, Allenex, Biocept, Biodesix, CareDx, Guardant Health, Illumania, Invited, Natera, Quest Diagnostics, Roche Holdings, Sequenom, Trovagene.
The cell-free dna (cfdna) testing market is expected to register a CAGR of 16.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cell-Free DNA (cfDNA) Testing Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cell-Free DNA (cfDNA) Testing Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cell-Free DNA (cfDNA) Testing Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cell-Free DNA (cfDNA) Testing Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cell-Free DNA (cfDNA) Testing Market Size & Forecast, 2018-2028
4.5.1 Cell-Free DNA (cfDNA) Testing Market Size and Y-o-Y Growth
4.5.2 Cell-Free DNA (cfDNA) Testing Market Absolute $ Opportunity
Chapter 5 Global Cell-Free DNA (cfDNA) Testing Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cell-Free DNA (cfDNA) Testing Market Size Forecast by Type
5.2.1 Donor-Derived Cell-Free DNA (DdcfDNA)
5.2.2 Circulating Cell-Free Tumor DNA (CtDNA)
5.2.3 Cell-Free Fetal DNA (NIPT)
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cell-Free DNA (cfDNA) Testing Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cell-Free DNA (cfDNA) Testing Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Ambulatory Surgical Centers
6.2.3 Cancer Research Institutes
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cell-Free DNA (cfDNA) Testing Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cell-Free DNA (cfDNA) Testing Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cell-Free DNA (cfDNA) Testing Analysis and Forecast
9.1 Introduction
9.2 North America Cell-Free DNA (cfDNA) Testing Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cell-Free DNA (cfDNA) Testing Market Size Forecast by Type
9.6.1 Donor-Derived Cell-Free DNA (DdcfDNA)
9.6.2 Circulating Cell-Free Tumor DNA (CtDNA)
9.6.3 Cell-Free Fetal DNA (NIPT)
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cell-Free DNA (cfDNA) Testing Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Ambulatory Surgical Centers
9.10.3 Cancer Research Institutes
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cell-Free DNA (cfDNA) Testing Analysis and Forecast
10.1 Introduction
10.2 Europe Cell-Free DNA (cfDNA) Testing Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cell-Free DNA (cfDNA) Testing Market Size Forecast by Type
10.6.1 Donor-Derived Cell-Free DNA (DdcfDNA)
10.6.2 Circulating Cell-Free Tumor DNA (CtDNA)
10.6.3 Cell-Free Fetal DNA (NIPT)
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cell-Free DNA (cfDNA) Testing Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Ambulatory Surgical Centers
10.10.3 Cancer Research Institutes
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cell-Free DNA (cfDNA) Testing Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cell-Free DNA (cfDNA) Testing Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cell-Free DNA (cfDNA) Testing Market Size Forecast by Type
11.6.1 Donor-Derived Cell-Free DNA (DdcfDNA)
11.6.2 Circulating Cell-Free Tumor DNA (CtDNA)
11.6.3 Cell-Free Fetal DNA (NIPT)
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cell-Free DNA (cfDNA) Testing Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Ambulatory Surgical Centers
11.10.3 Cancer Research Institutes
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cell-Free DNA (cfDNA) Testing Analysis and Forecast
12.1 Introduction
12.2 Latin America Cell-Free DNA (cfDNA) Testing Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cell-Free DNA (cfDNA) Testing Market Size Forecast by Type
12.6.1 Donor-Derived Cell-Free DNA (DdcfDNA)
12.6.2 Circulating Cell-Free Tumor DNA (CtDNA)
12.6.3 Cell-Free Fetal DNA (NIPT)
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cell-Free DNA (cfDNA) Testing Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Ambulatory Surgical Centers
12.10.3 Cancer Research Institutes
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cell-Free DNA (cfDNA) Testing Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cell-Free DNA (cfDNA) Testing Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cell-Free DNA (cfDNA) Testing Market Size Forecast by Type
13.6.1 Donor-Derived Cell-Free DNA (DdcfDNA)
13.6.2 Circulating Cell-Free Tumor DNA (CtDNA)
13.6.3 Cell-Free Fetal DNA (NIPT)
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cell-Free DNA (cfDNA) Testing Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Ambulatory Surgical Centers
13.10.3 Cancer Research Institutes
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cell-Free DNA (cfDNA) Testing Market: Competitive Dashboard
14.2 Global Cell-Free DNA (cfDNA) Testing Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Agilent Technology
14.3.2 Allenex
14.3.3 Biocept
14.3.4 Biodesix
14.3.5 CareDx
14.3.6 Guardant Health
14.3.7 Illumania
14.3.8 Invited
14.3.9 Natera
14.3.10 Quest Diagnostics
14.3.11 Roche Holdings
14.3.12 Sequenom
14.3.13 Trovagene
